+48 601 539 077 mmjurczy@cyf-kr.edu.pl

Biographical Note

Prof. Dr. Artur Jurczyszyn, M.D.

Head of the Center for the Treatment of Plasmocytic Dyskrasias.
Department of Hematology, Jagiellonian University CM Chair and Department of Hematology, University Hospital in Krakow, Poland

Internal medicine specialist and hematologist specialist, employed as a professor at the Department of Hematology, Jagiellonian University CM, Krakow. Current clinical and scientific activities are particularly concerned with issues related to the treatment of plasmocytic dyscrasias. Author of more than 250 scientific publications with a total impact factor > 900, Hirsch index 25; editor of seven book monographs in the field of clinical hematology. Prof. Jurczyszyn is a member of the Presidium of the Polish Myeloma Group of the Polish Society of Hematologists and Transfusionologists, the International Multiple Myeloma Working Group (IMWG), the European Society of Hematology (EHA), the American Society of Hematology (ASH), the International Myeloma Society (IMS). In 1996 graduated from the Faculty of Medicine of the Jagiellonian University, in 2003 he defended his doctoral thesis on the importance of cytokines in the pathogenesis of multiple myeloma, in 2016 he obtained a post-doctoral degree in medical sciences for a series of publications on the biology and treatment of multiple myeloma. The most important publications include: 1) a work on prognostic factors in primary plasma cell leukemia (Br J Haematol. – 2018), 2) a work describing the world’s largest group of 172 patients with central nervous system infiltrates in the course of multiple myeloma (Am J Hematol. – 2016), 3) a multicenter, retrospective study describing 53 histopathologically confirmed cases of secondary skin invasion by myeloma (Leuk Lymphoma – 2016); 4) a study showing a retrospective comparison of 50 cases of biclonal myeloma with 50 cases of classic MM (Ann Hematol. – 2017), 5) a multicenter, retrospective study covering the world’s largest group of 134 patients with IgM MM (Am J Hematol. – 2017), 6 ) a study comparing 173 young patients with MM (21-40 years of age) with a group of 916 patients aged 41-60 years – the largest analysis regarding prognostic factors and clinical characteristics of young patients with MM treated with new drugs (Br J Haematol. – 2016), 7 ) a study describing 101 cases of secondary plasma cell leukemia, clinical characteristics and possibilities of optimal treatment in this difficult clinical situation (Leuk Lymphoma – 2018), 8) a multicenter, retrospective study describing 127 patients with extramedullary form of MM due to hematogenous hyperplasia, which showed a very short 6-month survival and it has been proven that immunomodulatory drugs may be more effective than other methods of therapy (Am J Hematol. – 2019). 9) a multicenter, retrospective study describing 85 patients with multiple myeloma doubly resistant to immunomodulatory drugs and proteasome inhibitors. This is a difficult-to-treat group of patients who definitely benefit from a bone marrow transplant procedure performed immediately without other emergency treatment (Leuk Lymphoma – 2020). 10) a retrospective study describing the world’s largest group of 223 patients with a rare cytogenetic change t(14;16) in the course of multiple myeloma. A detailed analysis and clinical and laboratory description of the patients confirmed the high risk and poor prognosis of this group of patients (Am J Hematol. – 2020). While working scientifically in recent years, he created a multi-person and multi-center international research group (Prof. Morie A. Gertz Mayo Clinic, USA; Prof. Ruben Niesvizky, Cornell University, USA, Prof. Jorge J. Castillo, Harvard University, USA, Prof. Kenneth Anderson, Dana Farber Cancer Center, USA, Prof. David H. Vesole, Hackensack University, USA, Prof. Roman Hajek, University of Ostrava, Czech Republic), which focuses on the clinic of rare plasmacytic dyscrasias. He completed research internships at the John Theurer Cancer Institute in Hackensack (2012) and at the Dana Farber Cancer Institute in Boston (2014). In 2015, he was honored with the 650th anniversary medal of the Jagiellonian University in recognition of his many years of medical and scientific work. In 2016, he received the “Amicus hominum” distinction – for people working for the good of others from the Marshal of the Lesser Poland Voivodeship. In 2017, he was awarded the 1st degree award of the Minister of Science and Higher Education for scientific achievements, and in 2018 he received the award. Tadeusz Browicz from the Polish Academy of Sciences in Krakow for developing an original prognostic index in primary plasma cell leukemia. Co-founder and president of the Myeloma Treatment Center Foundation, which has been operating since 2008, and is a public benefit organization. Since 2017, he has been the Chairman of the Krakow Branch of the Polish Society of Hematologists and Transfusionologists, and also the Plenipotentiary of the Dean of the Faculty of Medicine of the Jagiellonian University Medical College. From October 1, 2018 to May 22, 2019, he was the Head of the Clinical Department of Hematology at the University Hospital in Krakow. In February 2021, on the anniversary of the birth of Nicolaus Copernicus, he was honored with the award of the Minister of Education and Science for significant achievements in the field of scientific activity. By order of the President of the Republic of Poland, Andrzej Duda of September 28, 2021, he was awarded the title of professor of medical and health sciences in the discipline of medical sciences. Non-medical interests: film, theater, jazz music, travel, skiing and tourism.

Publications and citations by GOOGLE SCHOLAR [zobacz listę publikacji]
Publications in the PUBMED database [zobacz listę publikacji]